Sirtuin 1 activator SRT 2104 protects Huntington's disease mice
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Sirtuin 1 is a nicotinamide adenine dinucleotide‐dependent protein deacetylase which regulates longevity and improves metabolism. Activation of Sirtuin 1 confers beneficial effects in models of neurodegenerative diseases. We and others have provided convincing evidence that overexpression of Sirtuin 1 plays a neuroprotective role in mouse models of Huntington's disease. In this study, we report that SRT 2104, a small molecule Sirtuin 1 activator, penetrated the blood–brain barrier, attenuated brain atrophy, improved motor function, and extended survival in a mouse model of Huntington's disease. These findings imply a novel therapeutic strategy for Huntington's disease by targeting Sirtuin 1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Huntington disease: natural history, biomarkers and prospects for therapeutics
Ross, C. A., Aylward, E. H., Wild, E. J., Langbehn, D. R., Long, J. D., Warner, J. H., Scahill, R. I., Leavitt, B. R., Stout, J. C., Paulsen, J. S., et al. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.24 · Cited by 1,016 · cited 1×
“Currently, there are no pharmacological interventions available to delay the onset or reverse the progression of this devastating disease.(1) Previously, we and others have provided convincing evidence that genetically increasing Sirtuin 1 (SIRT1) shows neuroprotection in several mouse models of HD, whereas a deficien…”
BackgroundDuan, W., Guo, Z., Jiang, H., Ware, M., Li, X.-J., & Mattson, M. P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0536856100 · Cited by 428 · cited 1×
“Male mice were used in our studies as reported previously.(13) SRT2104 (>98% purity) was synthesized by Sirtris, a GlaxoSmithKline company.”
MethodSelf-citationGräff, J., Kahn, M., Samiei, A., Gao, J., Ota, K. T., Rei, D., & Tsai, L.-H. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.5657-12.2013 · Cited by 124 · cited 1×
“Moreover, STACs extended lifespan in mice fed the regular diet and protected neurons against degeneration in Alzheimer’s disease models.(8,9) In this study, we validated the brain penetration of SRT2104, a newly characterized STAC,(10) and found that SRT2104 improved motor performance on the balance beam, attenuated b…”
Background
Cited by
Brain metabolism in health, aging, and neurodegeneration
Camandola, S., & Mattson, M. P. (2017) · The EMBO Journal · doi:10.15252/embj.201695810 · Cited by 752
Role of Sirtuin1-p53 regulatory axis in aging, cancer and cellular reprogramming
Ong, A. L. C., & Ramasamy, T. S. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.02.004 · Cited by 301
Sirtuins and Their Roles in Brain Aging and Neurodegenerative Disorders
Jęśko, H., Wencel, P., Strosznajder, R. P., & Strosznajder, J. B. (2017) · Neurochemical Research · doi:10.1007/s11064-016-2110-y · Cited by 259
The Role of Sirtuins in Cellular Homeostasis
Kupis, W., Pałyga, J., Tomal, E., & Niewiadomska, E. (2016) · Journal of Physiology and Biochemistry · doi:10.1007/s13105-016-0492-6 · Cited by 200
The road ahead for health and lifespan interventions
Gonzalez-Freire, M., Diaz-Ruiz, A., Hauser, D., Martinez-Romero, J., Ferrucci, L., Bernier, M., & de Cabo, R. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101037 · Cited by 118
Metadata
- Authors
- Jiang, M., Zheng, J., Peng, Q., Hou, Z., Zhang, J., Mori, S., Ellis, J. L., Vlasuk, G. P., Fries, H., Suri, V., & Duan, W.
- Venue
- Annals of Clinical and Translational Neurology
- Publisher
- Wiley
- Published
- 2014-10-31
- Volume
- 1
- Issue
- 12
- Pages
- 1047-1052
- ISSN
- 2328-9503 (ISSN-L)
- OpenAlex
- W2038666430
- Cited by
- 54
- References
- 3
- FWCI
- 1.88
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.